目次

Contents

1. Executive Summary

2. Peptic Ulcer Drugs Market
2.1. Product Overview
2.2. Market Definition
2.3. Segmentation
2.4. Assumptions and Acronyms

3. Research Methodology
3.1. Research Objectives
3.2. Primary Research
3.3. Secondary Research
3.4. Forecast Model
3.5. Market Size Estimation

4. Average Pricing Analysis

5. Market Dynamics
5.1. Growth Drivers
5.2. Restraints
5.3. Opportunity
5.4. Trends

6. Correlation & Regression Analysis
6.1. Correlation Matrix
6.2. Regression Matrix

7. Recent Development, Policies & Regulatory Landscape

8. Risk Analysis
8.1. Demand Risk Analysis
8.2. Supply Risk Analysis

9. Peptic Ulcer Drugs Market Analysis
9.1. Porters Five Forces
9.1.1. Threat of New Entrants
9.1.2. Bargaining Power of Suppliers
9.1.3. Threat of Substitutes
9.1.4. Rivalry
9.2. PEST Analysis
9.2.1. Political
9.2.2. Economic
9.2.3. Social
9.2.4. Technological

10. Peptic Ulcer Drugs Market
10.1. Market Size & forecast, 2019A-2030F
10.1.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.1.2. By Volume (Million Units) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

11. Peptic Ulcer Drugs Market: Market Segmentation
11.1. By Regions
11.1.1. North America:(U.S. and Canada)
11.1.1.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.1.2. Latin America: (Brazil, Mexico, Argentina, Rest of Latin America)
11.1.2.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.1.3. Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe)
11.1.3.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.1.4. Asia-Pacific: (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific)
11.1.4.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.1.5. Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of Middle East and Africa)
11.1.5.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

12. Peptic Ulcer Drugs Market: Market Segmentation
12.1. By disease indication: Market Share (2020-2030F)
12.1.1. gastric ulcers, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.1.2. duodenal ulcers, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.1.3. esophageal ulcers, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.2. By application : Market Share (2020-2030F)
12.2.1. hospital pharmacies, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.2.2. drug stores, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.2.3. retail store, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.2.4. online sales, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

13. Company Profile
13.1. Eumedica
13.1.1. Company Overview
13.1.2. Company Total Revenue (Financials)
13.1.3. Market Potential
13.1.4. Global Presence
13.1.5. Key Performance Indicators
13.1.6. SWOT Analysis
13.1.7. Product Launch
13.2. Takeda Pharmaceutical Co. Ltd.
13.3. Taiho Pharmaceutical
13.4. Ferring Pharmaceuticals
13.5. PharmaKing
13.6. Zuventus Healthcare
13.7. Otsuka Holdings
13.8. Daiichi Sankyo
13.9. Johnson and Johnson
13.10. Other prominent players
Consultant Recommendation
**The above-given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.